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To investigate the mechanism by which HSulf-1 expres-
sion is downregulated in ovarian cancer, DNA methyla-
tion and histone acetylation of HSulf-1 was analysed in
ovarian cancer cell lines and primary tumors. Treatment
of OV207 and SKOV3 by 5-aza-20-deoxycytidine resulted
in increased transcription of HSulf-1. Sequence analysis
of bisulﬁte-modiﬁed genomic DNA from ovarian cell lines
and primary tumors without HSulf-1 expression revealed
an increase in the frequency of methylation of 12 CpG
sites in exon 1A. Chromatin immunoprecipitation assays
showed an increase in histone H3 methylation in cell lines
without HSulf-1 expression. To assess the signiﬁcance of
HSulf-1 downregulation in ovarian cancer, OV167 and
OV202 cells were transfected with HSulf-1 siRNA.
Downregulation of HSulf-1 expression in OV167 and
OV202 cells lead to an attenuation of cisplatin-induced
cytotoxicity. Moreover, patients with ovarian tumors
expressing higher levels of HSulf-1 showed a 90%
response rate (27/30) to chemotherapy compared to a
response rate of 63% (19/30) in those with weak or
moderate levels (P¼ 0.0146, v2 test). Collectively, these
data indicate that HSulf-1 is epigenetically silenced in
ovarian cancer and that epigenetic therapy targeting
HSulf-1 might sensitize ovarian tumors to conventional
ﬁrst-line therapies.
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Introduction
DNA methylation and covalent modiﬁcation of histone
proteins are two epigenetic modiﬁcations important in
transcriptional control (Jones and Baylin, 2002). Hyper-
methylation of CpG-rich sequences present in the
promoters of genes is associated with gene silencing.
Epigenetic silencing of tumor suppressor genes is at least
as common as mutation as a mechanism of gene
inactivation. A broad spectrum of genes belonging to
different classes of activity such as DNA repair (Esteller
et al., 2002), cell cycle control (Xing et al., 2004),
signal transduction (Terasawa et al., 2004), angiogenesis
(Yang et al., 2003) and invasion (Seidl et al., 2004) are
inactivated by DNA methylation in cancer cells. The
second layer of epigenetic transcriptional control is
histone modiﬁcation such as acetylation, methylation,
phosphorylation and ubiquitination (LaVoie, 2005). Of
these modiﬁcations, acetylation is controlled by histone
acetyltransferases and histone deacetylases (HDACs)
which control gene expression by remodeling the
nucleosomes leading to either transcriptional activation
or repression, respectively (Kondo et al., 2004). Two
chemical agents commonly used to modulate the
expression of silenced genes in cancer cells are 5-aza-
20-deoxycytitdine (5-aza-dC), which is an inhibitor of
DNA methylation and trichostatin A (TSA), an
inhibitor of histone deacetylation (Marks et al., 2001;
Johnstone, 2002; Yamashita et al., 2002). Gene expres-
sion studies revealed that the effects of 5-aza-dC are
similar to those of TSA exposure than either of the
somatic cell DNA methyltransferase knockouts (DNMT
knockouts), implying a converging mechanism for these
agents (Gius et al., 2004).
We have identiﬁed recently HSulf-1 as a down-
regulated gene in several tumor types including ovarian
and breast cancer cell lines and primary ovarian tumors
(Lai et al., 2003, 2004a, b). Our initial analysis indicated
that loss of heterozygosity (LOH) may represent a
mechanism of HSulf-1 inactivation in ovarian tumors.
However, this mechanism alone could not account for
complete loss of HSulf-1 expression in cell lines and in
some primary tumors (Lai et al., 2003) as it would
require deletion of both alleles. Therefore, additional
mechanisms of inactivation could also play a role in
inactivating HSulf-1 expression. Our sequence analysis
of HSulf-1 promoter revealed putative CpG-rich
sequences in Exon 1A (Lai et al., 2003). This fragment
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(Z58846) was also identiﬁed as a putative CpG-rich
sequence in previous study (Cross et al., 1994). In this
study, we report on the methylation status of this
putative CpG island in ovarian cell lines and primary
ovarian tumors by direct sequencing of the bisulﬁte-
modiﬁed DNA. In addition, we also performed chro-
matin immunoprecipitation (ChIP) (Orlando, 2000)
assays to analyse the acetylation status of HSulf-1
promoter. Our results also implicate HSulf-1 in modu-
lating the chemoresponse to cisplatin and provide the
evidence of CpG and histone methylation as a mechan-
ism of HSulf-1 inactivation.
Results
Treatment with a demethylating agent and/or a histone
deacytelase inhibitor can reactivate HSulf-1 expression in
ovarian cancer cell lines
To examine the relative contributions of DNA methyla-
tion and histone deacetylation in silencing of HSulf-1
expression, we determined the effects of treatment with a
demethylating agent 5-aza-dC, in ovarian cancer cell
lines SKOV3 and OV207 without HSulf-1 expression
(Figure 1a). Semi-quantitative reverse transcription–
polymerase chain reaction (RT–PCR) results indicated
that treatment with 5-aza-dC resulted in reactivation of
HSulf-1 transcription in SKOV3 and OV207 cells
(Figure 1b and c). In addition, treatment of OV207
cells with 5-aza-dC in combination with TSA resulted in
an increase in the reactivation of HSulf-1 expression
compared to 5-aza-dC treatment alone (Figure 1d).
These results suggest that gene silencing as a result of
CpG methylation also involves recruitment of chroma-
tin modifying factors such as HDACs.
Methylation-associated silencing of HSulf-1 in ovarian
cell lines and primary ovarian tumors
Primers encompassing 12 CpG sites within the CpG-rich
region in Exon 1A of HSulf-1 (Cross et al., 1994; Lai
et al., 2003) were designed to amplify and sequence
the bisulﬁte-modiﬁed DNA as described previously
(Herman et al., 1996; Shridhar et al., 2001). Overall
methylation was determined for a subset of cell lines and
primary ovarian tumors (fresh frozen) with or without
HSulf-1 expression. HSulf-1-deﬁcient cell lines such as
OV207, SKOV3OVCAR3 and OVCAR5 and primary
ovarian tumors (OV34, 45, 97, 102, 121, 235, 259, 518
and 731) exhibited extensive methylation of the CpG
island (Table1 and Figure 2a and b). However, CpG
sites 7–11 were unmethylated in the HSulf-1-expressing
cell lines (VOSE, OV167, OV202), and frequently hemi-
methylated in primary ovarian tumors (OV522, OV715
and OV220) (Table 1). Subsequently, sequencing of
bisulﬁte-modiﬁed DNA in nonexpressing cells treated
with 5-aza-dC revealed methylation of sites 1–4 and
complete demethylation of sites 9 and 11 (in OV207),
sites 6–8 (in SKOV3) and site 10 (in OVCAR5). These
results suggest that methylation status of CpG sites 5–12
could reﬂect the transcriptional silencing of HSulf-1.
Both semi-quantitative and RT–PCR results of tumors
and cell lines are also included in Table 1.
Methylation of the CpG island was associated with
chromatin change
In OV207, treatment with 5-aza-dC plus TSA resulted in
robust HSulf-1 expression (Figure 1c), indicating the
potential involvement of DNA and histone methylation.
To investigate this, ChIP assays were used to assess the
acetylation/methylation status before and after 5-aza-
dC or TSA treatment. The diagrammatic representation
of HSulf-1 CpG island is shown in Figure 3a. ChIP
analysis of OV207 cells treated with 5-aza-dC or TSA
exhibited increased histone acetylation, compared with
untreated OV207 (Figure 3b). Quantiﬁcation of the
histone acetylation levels is indicated in the histogram
(Figure 3c). To compare the acetylation and methyla-
tion status in cell lines, ChIP analyses were performed
in OV207, SKOV3 and OV202 cells using three set of
primers encompassing the CpG island. OV207 and
SKOV3 cell lines, which do not express HSulf-1, showed
an increase in the levels of histone H3 K9 methylation
(Figure 3d and e) compared to OV202 cell line
(Figure 3f). HSulf-1 expressing OV202 showed >4-fold
decrease in methylation of chromatin (histone H3 at K9)
compared to OV207 or SKOV3 (Figure 3g). PCR-
optimized ChIP analysis of H3 acetylation across cell
lines revealed >4 increase in H3 acetylation in OV202
compared to SKOV3 cells (Figure 3h and i). Collectively
these results indicate that HSulf-1 expression is under
epigenetic control.
Re-expression of HSulf-1 by demethylating agent
sensitizes cancer cells to cisplatin treatment
Our previous study showed that HSulf-1 expression
conferred sensitivity to cisplatin and taxol (Lai et al.,
2003, 2004b). HSulf-1 represents a potential target of
epigenetic therapy to re-sensitize cancer cells to cisplatin
and taxol. Epigenetic therapy has been successfully used
in vitro to overcome drug resistance (Balch et al., 2004).
Figure 1 HSulf-1 expression in ovarian cell lines and in OV207
treated with 5-aza-dC and TSA. (a) RT–PCR products of HSulf-1
and control GAPDH were visualized by agarose gel electrophoresis
with ethidium bromide in ovarian cancer cell lines. (b–c) Expression
of the HSulf-1 gene is induced with 2.5mM 5-aza-dC and 0.5mM
TSA treatments. A synergistic effect of 2.5 mM 5-aza-dC and 0.5 mM
TSA combined treatment results in increased expression of HSulf-1.
w, water.
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Therefore, we tested whether re-expression of HSulf-1
by epigenetic therapy could overcome drug resistance.
HSulf-1 expression was induced by 5-aza-dC treatment
in OV207 and followed by cisplatin treatment. Surviving
cells were assayed for (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) (MTT) reduction 3 days
following cisplatin treatment. As shown in Figure 4a,
induction of HSulf-1 in OV207 cells sensitized these cells
to cisplatin-induced cytotoxicity.
Speciﬁc contribution of HSulf-1 in conferring
chemosensitivity to ovarian cancer cells
As 5-aza-dC treatment also induces several epigeneti-
cally silenced genes, we could not fully evaluate the
contribution of HSulf-1 re-expression on chemosensi-
tivity. Therefore, we opted to silence HSulf-1 in OV167
and OV202 cells with endogenous HSulf-1 expression.
Scrambled (scr) small interfering RNA (siRNA) served
as controls (Figure 4b and c). These experiments
were repeated twice with the same results. As shown in
Figure 4b and c, there was an increase in the survival
following cisplatin treatment in the cells pretreated
with HSulf-1 siRNA compared with control cells treated
with scr siRNA. The speciﬁc contribution of HSulf-1
was evaluated by re-expressing HSulf-1 following
siRNA-mediated downregulation in OV167 cells.
Re-expression of HSulf-1 rescued cisplatin sensitivity
in OV167 cells.
Effect of HSulf-1 expression on clinical chemosensitivity
On the basis of our observation that HSulf-1 confers
chemosensitivity in vitro, we tested whether HSulf-1
expression would correlate with chemoresponse in vivo.
HSulf-1 expression was determined by RNA in situ
hybridization using HSulf-1 riboprobes on a tissue
microarray (TMA) containing 60 primary epithelial
ovarian tumors. Patient characteristics are described in
Table 2. All patients had advanced-stage disease,
and the majority received optimal debulking surgery.
Representative staining intensities corresponding to low,
moderate and high levels of HSulf-1 expression are
shown in Figure 5. Independently, tumor response to
Table 1 HSulf-1 methylation analysis in ovarian cell lines and primary ovarian tumors
Sample 1 2 3 4 5 6 7 8 9 10 11 12 RT–PCR PCR DCt LOH
(A) Analysis of the methylation status of sites 1–12 within HSulf-1 exon 1A in ovarian cell lines and primary ovarian tumors and its corresponding
expression levels
Ovarian cell lines
VOSE     ~ J J J J J J  + 4.6 ND
OV 167     J J J J J J J  + 5.49 ND
OV 202     J J J J J J J  + 5.43 ND
OV 207     ~  ~   J    18.1 ND
OVCAR 3              10.33 ND
OVCAR 5              15.19 ND
SKOV3       ~ J      14.44 ND
Primary ovarian tumors
OV 102        J      10.45 +
OV 518             ND ND ND
OV 522     ~  ~ ~ ~ ~ ~ ~ + 3.26 ND
OV 687          ~ ~   8.15 ND
OV 715        ~ ~ ~ ~ ~ + 3.82 ND
OV 731          ~    ND ND
OV 734          ~ ~   9.91 ND
OV 34              6.17 ND
OV 45        J      7.88 ND
OV 97     ~   ~   ~   10.73 
OV 98     ~   ~  ~ ~  weak 5.78 +
OV 121              13.08 
OV 183        ~      6.99 +
OV 220     ~  ~ ~ ~   ~ + 5.07 
OV 235          ~ ~   7.66 ND
OV 259              10.98 ND
(B) Analysis of the methylation status of sites 1–12 in OV207, OVCAR5 and SKOV3 before and after treatment with 5-Aza-dC. Empty circles –
unmethylated, ﬁlled circles-methylated and circles with a line-hemimethylated. HSulf-1 mRNA expression by semi-quantitative RT–PCR and real-time
PCR and HSulf-1 LOH status are also indicated.
OV 207     ~  ~   J   
OV 207+5-Aza-dC     ~ ~ ~  J J J ~ +
OVCAR 5             
OVCAR5+5-AZA-dC         ~ J   weak
SKOV3       ~ J     
SKOV3+5-Aza-dC      J J J     +
Abbreviations: LOH, loss of heterozygosity; ND, not determined; RT–PCR, reverse transcription – polymerase chain reaction
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chemotherapy was deﬁned as complete response (CR),
partial response (PR) and no response (NR) as
described previously (Chien et al., 2006). Responders
were deﬁned as those patients who showed CR or PR to
chemotherapy. Nonresponders were deﬁned as those
patients who showed NR to chemotherapy as described
above. As there is no statistically signiﬁcant difference
between low-staining group vs moderate-staining group,
these two groups were combined and reanalysed against
high level staining group by w2 test. As shown in
Figure 5c, tumors with high levels of HSulf-1 showed
90% (27/30) response rate compared to 63% (19/30)
response rate in tumors with low to moderate levels of
HSulf-1. The odds ratio for not responding to therapy
in cohort with low levels of HSulf-1 was 6.0 (95%
conﬁdence interval, 1.481–24.31). These results suggest
that HSulf-1 expression inﬂuences tumor response to
chemotherapy in patients. As all patients analysed had
Figure 2 Methylation analysis of HSulf-1 by genomic sequencing of bisulﬁte modiﬁed DNA in ovarian cell lines and primary ovarian
tumors. (a) Sequence chromatograms of CpG sites 6–12 of bisulﬁte modiﬁed DNA from ovarian cell lines. OV207 and SKOV 3 (1–2)
without HSulf-1 expression show methylation of several CpG sites whereas none of these site are methylated in VOSE, OV202 and
OV167 (3–5) with HSulf-1 expression. HSulf-1 expression in these cell lines are indicated as þ for expression and – for no expression.
Sequence chromatograms of CpG sites 6–12 of bisulﬁte-modiﬁed DNA from primary ovarian tumors. Chromatograms 1–2: tumors
OV522 and OV715 with HSulf-1 expression by RT–PCR show hemimethylation of several cytosine residues after sodium bisulﬁte
treatment as shown by N in the sequence chromatograms. Chromatograms 3–6: tumor samples (OV34, OV121, OV518 and OV259)
without HSulf-1 expression show methylation of all six CpG sites 6–12.
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advanced stage disease with mostly serous histology, no
correlation of HSulf-1 expression to stage, grade or
histology was performed. The speciﬁcity of the ribop-
robe used in RNA in situ was determined on the
TMA using a sense probe. Figure 5e and f show
the hybridization signal from one of the sections on
the TMA with the antisense and the sense probe
respectively.
Discussion
Epigenetics is a widely accepted mechanism of silencing
gene expression in cancer. Epigenetic modiﬁcations of
DNA and histones are involved in gene regulation by
altering chromatin structure (Fujii et al., 2003). In this
report we demonstrated that DNA methylation and
histone modiﬁcations regulate HSulf-1 expression and
Figure 3 ChIP analysis of histone H3 acetylation associated with HSulf-1 CpG island in ovarian cell lines. (a) Diagrammatic
representation of HSulf-1 CpG island showing CpG sites (vertical lines), location of 12 CpG sites in Exon 1A and location of primers
used in ChIP analysis. (b) OV207 cells treated with 5-aza-dC and TSA show increased acetylation as indicated by increased band
intensities following ChIP with CpG3 primers. (c) Acetylation levels are expressed as the ratio of signal intensity of
immunoprecipitated product (acetylated DNA-IP) to input as described in the Materials and methods section. OV207 treated with
5-aza-dC and TSA show increased ratios compared to untreated parental control. (d–e) ChIP assays using CpG1, CpG2 and CpG3
primers encompassing the HSulf-1 CpG island in OV207 and SKOV3 show the equivalent level of histone H3 acetylation (H3 ac. K9)
over methylation (H3 me K9) of chromatin associated with HSulf-1 CpG island. (f) ChIP assays indicate higher levels of H3
acetylation compared to methylation in OV202. ChIP assays with anti-RNA polymerase II (Pol II) and control IgG (cont. IgG)
represents positive and negative controls, respectively. PCR using negative primers (neg. Primers) ﬂanking a region of genomic DNA
between GAPDH gene and CNAP1 gene represents speciﬁcity of ChIP reactions. Independent ChIP experiments were repeated at least
three times to conﬁrm the reproducibility of these results. (G) The ratios of acetylation/methylation of histone H3 at K9 in OV207,
SKOV3 and OV202 were determined by ChIP using CpG1, CpG2 and CpG3 primers encompassing the HSulf-1 CpG island. (H) ChIP
analysis using CpG1, CpG2 and CpG3 primers encompassing the HSulf-1 CpG island in OV202 and SKOV3 indicates higher levels of
acetylated histone H3 K9 in HSulf-1 expressing OV202 cells compared to HSulf-1-deﬁcient SKOV3 cells. (i) Histogram showing fold
change in acetylated histone H3 K9 in OV202 cells over SKOV3 cells as determined by ChIP using CpG1, CpG2 and CpG3 primers
encompassing the HSulf-1 CpG island.
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provided the ﬁrst evidence of methylation in com-
bination with chromatin histone modiﬁcation as a
mechanism of HSulf-1 inactivation in ovarian cancer.
Re-expression of HSulf-1 has been shown to inhibit
tumor growth (Dai et al., 2005; Lai et al., 2006; Narita
et al., 2006). In this study, we analysed the relationship
between HSulf-1 induction with 5-aza-dC and chemo-
response of ovarian cancer cell lines in vitro and
correlated HSulf-1 expression in patient samples to a
better therapeutic index.
Nonpromoter CpG-island methylation has been
shown to be more susceptible to aberrant methylation
(Douglas et al., 2004). In addition, the density and the
number of methylated CpG dinucleotides can exert
transcriptional repression over long distances (Nguyen
et al., 2001). We therefore analysed the methylation
status of the CpG island within Exon 1A. On the basis
of data on primary tumors and cell lines before
treatment, we conclude that CpG sites 5–12 could play
a role in HSulf-1 transcriptional control. We observed
an increase in the frequency of methylated CpGs in
tumors and cell lines with HSulf-1 loss. On the basis
of the data on primary tumors and cell lines before after
5-aza-dC treatment, we conclude that CpG sites 5–12
could play a role in HSulf-1 transcriptional control.
Data from Galm et al., (2002) suggest that increasing the
50aza-20-deoxycytidine (DAC) dose beyond a certain
level does not necessarily result in higher demethylating
capacity within a given time course, but rather reaches a
plateau phase of demethylation .
In addition to this epigenetic modiﬁcation, we
also analysed histone acetylation as another mechanism
of epigenetic control in this region as histone hypo-
acetylation is another commonly occurring epigenetic
modiﬁcation in silenced genes. In many tumors, includ-
ing ovarian cancers, deacetylation-induced silencing of
genes such as p21CIP1/WAF1 (Blagosklonny et al.,
2002) and gelsolin (Han et al., 2000) is well documented
(Balch et al., 2004). Highly acetylated histones are
usually associated with transcriptionally active se-
quences and hypoacetylated histones with silenced
genes. Consistent with these results, we observed higher
levels of histone H3 (K9) acetylation over methylation
in HSulf-1 expressing OV202. In contrast, higher
levels of histone H3 (9) methylation were observed in
HSulf-1 silenced OV207 and SKOV3 (Figure 3c). These
results suggest that gene silencing as a result of DNA
Figure 4 Re-expression of HSulf-1 promotes cisplatin toxicity in vitro. (a) OV207 cells treated for 48 h with 5-aza-dC, the cells were
exposed to varying concentrations of cisplatin for 24 h and assayed by MTT reduction assay. 5-aza-dC-treated OV207 cells were less
sensitive to cisplatin treatment compared to untreated controls. (b and c) Following HSulf-1 suppression by siRNA, OV202 (b) and
OV167 (c) cells were treated with varying concentrations of cisplatin ranging from 2.5 to 40 mM for 24 h, and viable cells assayed by
MTT. Suppression of HSulf-1 results in signiﬁcant attenuation of cisplatin toxicity in OV202 and OV167 cells (HSulf-1 siRNA) ()
compared to scr siRNA-transfected cells (’) or in OV167 cells (c) expressing HSulf-1 siRNA þHSulf-1 ORF plasmid (D). As siRNA
was targeted towards 30 UTR of HSulf-1, siRNA transfection did not affect exogenous expression of HSulf-1 (Rescue) by plasmid
containing HSulf-1 open reading frame. Inset in (c) analysis of HSulf-1 expression by RT–PCR indicates that transient expression of
siRNA against HSulf-1 effectively suppressed endogenous expression of HtrA1 in OV167 cells (top panel, lane 2). Scr siRNA did not
affect endogenous expression of HSulf-1 (lane 1). Level of HSulf-1 following rescue (top panel, lane 3. Lower panel shows GAPDH
loading controls.
Table 2 Ovarian cancer patient characteristics
No. subjects 60
Median age at diagnosis 61 (38–80)
No. alive at the time of analysis 16 (26.66%)
Average length of follow-upa (months) 43.7
Chemotherapy, n
Cytoxan 13 (21.67%)
Taxol 47 (78.33%)
Primary surgery, n
Optimal debulking 53 (88.33)
Suboptimal 7 (11.67)
Stage, n
3 46 (76.66%)
4 14 (23.34%)
Grade, n
2 1 (1.67%)
3 30 (50%)
4 29 (48.33%)
Histology, n
Mixed 1 (1.67%)
Endometrioid 8 (13.33%)
Serous 51 (85%)
Pre-CA125, median (range) 830 (8.2–86 000)
Post-CA125, median (range) 12.05 (4.7–947)
aFollow-up refers to time from date of initial surgery to death or to
most recent follow-up visit. Pre-CA125, ovarian carcinoma antigen
CA125 levels before surgery; post-CA125, ovarian carcinoma antigen
CA125 levels after chemotherapy, measured in IU.
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methylation also involves recruitment of chromatin
modifying factors such as HDACs.
Ovarian cancer, although initially responsive to
conventional chemotherapeutic regimens, relapse after
a median period of 18 months (Greenlee et al., 2001).
The ability of a cancer cell to respond to a chemother-
apeutic agent is believed to be due, in part, to its
apoptotic capacity (Johnstone et al., 2002). It is now
evident that chemoresistant cells have downregulated
proapoptotic genes and/or overexpression of antiapop-
totic genes. Several genes involved in apoptotic path-
ways related to chemotherapeutic action in ovarian
cancer are downregulated by epigenetic mechanisms
(Makarla et al., 2005). Methylation of speciﬁc genes
such as hMLH1 has been shown to correlate with the
onset of tumor relapse after carboplatin/taxol therapy
in ovarian cancer patients (Gifford et al., 2004). In
addition, treatment of cisplatin-resistant A2780/CP
ovarian cancer cells with 5-aza-dC induced the
expression of hMLH1 and resensitized these cells to
cisplatin in a mouse xenograft model (Plumb et al.,
2000). Epigenetic downregulation of MCJ (DNAJC15)
(Shridhar et al., 2001; Strathdee et al., 2005), p16
(Katsaros et al., 2004), RASSF1A (Yoon et al., 2001;
Makarla et al., 2005) and hMLH1 possibly contributes
to resistance in ovarian and other cancers.
Although epigenetic therapies have been shown to
induce the re-expression of several tumor suppressor
genes and resensitize resistant tumors to conventional
drugs (Kopelovich et al., 2003), with the use of siRNA-
mediated gene silencing followed by rescue of the
protein expression, we have clearly shown that the
presence of HSulf-1 speciﬁcally contributes to cisplatin-
induced cytotoxicity. We initially tested the effect of
cisplatin cytotoxicity in HSulf-1 null OV207 cell line
following 5-aza-dC treatment. Our MTT assay clearly
indicated that 5-aza-dC treatment of these cells con-
ferred cisplatin sensitivity to these cells (Figure 4a).
However, as mentioned earlier, as several tumor
suppressor genes could be induced by this treatment,
we opted to downregulate HSulf-1 by siRNA-mediated
technology and assessed whether downregulation of
Figure 5 Expression of HSulf-1 correlates with patient response to chemotherapy. (a) Normal ovarian surface epithelium shows
speciﬁc staining for HSulf-1 by RNA in situ. (b) RNA in situ staining pattern in ovarian tumors on a TMA showing low (0), moderate
(1þ ) and high (2þ ) levels of HSulf-1. (c) A small section of TMA with three representative HSulf-1 expression levels is shown.
(d) Univariate analysis of chemoresponse showing signiﬁcant association between high levels of HSulf-1 expression and chemoresponse.
Tumors with high levels of HSulf-1 responded signiﬁcantly better than those with low levels as analysed by univariate analysis
(P¼ 0.0146). (e) A representative tumor on the TMA probed with the antisense HSulf-1 riboprobe. (f) The same tumor in E probed
with sense riboprobe for HSulf-1. The absence of staining in the sense-probed section indicates the speciﬁcity of the hybridization.
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HSulf-1 would result in resistance to cisplatin in a
HSulf-1 high expressing cell line, OV167. Whereas this
experiment clearly indicates that HSulf-1 downregula-
tion could confer resistance to cisplatin (Figure 4c), in
order to more speciﬁcally prove the contribution of
HSulf-1 in chemoresponse, we rescued the protein
expression following siRNA-downregulation in these
cells. The results from these experiments clearly
demonstrate that while full-length HSulf-1 could rescue
the cisplatin-induced cytotoxicity, the vector only control
did not (Figure 4c) and therefore implicate the contri-
bution of HSulf-1 in chemoresponse.
We emphasize that the increased resistance observed
with loss of HSulf-1 or an increased sensitivity observed
following rescue of HSulf-1 expression do not confer
absolute resistance or sensitivity to therapy. Rather,
these are relative changes compared to those observed
in control cells. However, these studies suggest that
expression of HSulf-1 may contribute to a better
therapeutic index.
Consistent with the in vitro data, our results also
implicate HSulf-1 in modulating chemoresponse to the
commonly used chemotherapeutic agents in vivo. Our
in vivo data (Figure 5) show 90% of patients (27/30) with
tumors expressing high levels of HSulf-1 responded to
chemotherapy with complete or partial clinical remis-
sions, whereas only 63% (19/30) of those with weak/
moderate levels of HSulf-1 expression respond favorably
to treatment (P¼ 0.0146, w2 test). These results have
considerable implications in the treatment options for
patients whose tumors no longer express HSulf-1.
Owing to the unavailability of fresh frozen samples that
is represented on the TMA, bisulﬁte sequencing of these
samples was not performed. We also emphasize that
the patients were selected at random, and most of the
patient tumors were optimally debulked to eliminate
the impact of residual disease on outcomes. Our data
demonstrate that HSulf-1 expression is correlated with
response to chemotherapy and thus may be useful in
conjunction with other molecular markers, in predicting
chemosensitivity. Given the observation that the pre-
sence of HSulf-1 also inhibits angiogenesis in vivo
(Narita et al., 2006), a combination therapy that
includes demethylating agents and or HDACs inhibitors
with classical antineoplastic drugs such as carboplatin
or taxol or antiangiogenic drug may beneﬁt patients
with tumors that lack HSulf-1 expression by promoting
the expression of epigenetically controlled genes
such as HSulf-1 involved in inhibiting growth and
angiogenesis.
Materials and methods
Cell culture
Five of eight ovarian-carcinoma cell lines (OV 167, OV 177,
OV 202, OV 207 and OV 266) were low-passage primary lines
established at the Mayo Clinic (Conover et al., 1998), whereas
OVCAR-5 and SKOV-3 were from American Type Culture
Collection (Manassas, VA, USA). All cells were grown
according to the providers’ recommendations.
Expression of HSulf-1 in primary ovarian tumors and cell lines
by real-time PCR
Duplex PCR ampliﬁcation was carried out using the primers
HSulf-1-F (50-AGACCTAAGAAT CTTGATGTTGGAA -30),
HSulf-1-R (50-CCATCCCATAACTGTCCTCTG -30), glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH)-F (5-ACC
CACTCCTCCACCTTTGA-30), GAPDH-R (50-ATGAGGT-
CCACCACCCTGTT-30). Reactions were run in an ABI PRISM
7700 Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) in the presence of SYBR-Green dye according
to the following condition: 2min at 501C and then 10min
at 951C for initial denaturation, followed by 40 cycles at 951C
(15 s), 601C (1min), followed by the measurement of ﬂuore-
scence at the end of each cycle. Each run included a negative
control and a known GAPDH control. Results from real-time
PCR were calculated as threshold cycles normalized to that
of the GAPDH gene according to the method of Overbergh
et al., (1999) and expressed as DCt values. Expression of
HSulf-1 by semi-quantitative RT–PCR was as previously
described (Lai et al., 2003). Two different sets of primers
were used. Primers 1929F (50-GAGCCATCTTCACCCATTC
AA-30), 2754R (50- TTCCCACCTTATGCCTTGGGT-30)
were used to analyse HSulf-1 expression in ovarian cell lines
(Figure 1a). Primers HSulf-1 F (50- CTCACAGTCCGG
CAGAGCACGCGGAAC-30) and HSulf-1 R (50- CACGGC
GTTGCTGCTATCTGCCAGCATCC-30) were used to
analyse induction of HSulf-1 following drug treatment
(Figure 1b–d).
Treatment of cells with TSA and 5-aza-dC
OV 207 cells were seeded at a low density in a 100mm tissue
culture dish and maintained for a total of 72 h. Mock
treatments consisted of identical volumes of absolute ethanol
or water. For 5-aza-dC (Sigma, St Louis, MO, USA)
treatment, drug was added after 24 h in culture and cells were
incubated for a total 48 h. Culture medium was exchanged
every 24 h for 5-aza-dC treatment. For combined treatment, 5-
aza-dC was added at 24 and 48 h time points and TSA (Sigma)
at 48 h time points only.
Genomic sequencing of bisulfite modified DNA
The methylation status of HSulf-1 was determined by genomic
sequencing of bisulﬁte-modiﬁed DNA as described previously
(Shridhar et al., 2001). The PCR primers used for bisulﬁte-
modiﬁed DNA are: MF: 50-TTTGGGGTCGGAGTCGGG
TCG -30 and MR:-50-TTCCTCATCTACCCTAACCTCC-30.
The conditions for ampliﬁcation were: 941C for 10min,
then 45 cycles of 941C for 30 s, 601C for 30 s and 721C for
30 s in an MJ Research Peltier Thermocycler (Waltham, MA,
USA).
ChIP
The ChIP assays for histone acetylation and methylation were
performed as described by Chadee et al. (1999). The presence
of the HSulf-1 CpG island in the immunoprecipitates was
detected by PCR using gene-speciﬁc primers as described
below. Individual ChIP assays were repeated three times to
conﬁrm the reproducibility. PCR ampliﬁcation was performed
using immunoprecipitated DNA or a 1:25 dilution of input
that had not been immunoprecipitated. Samples were heated
initially for 5min at 951C followed by 35 cycles of 951C for
30 s, 591C for 30 s and 721C for 30 s followed by a 7min
extension at 721C. The primer pairs for the HSulf-1 CpG
island were as follow: CpG1F, 50-AGCACTTGGTCTC
TGGAACG-30, CpG1-R, 50-TCGGGACACGGC TGAA
AGGA-30; CpG2-F, 50-TGCCTCTGCTCCTCCTCTTC-30,
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CpG2-R, 50-CCGATCAAGCCG CCCCGGC-30; CpG3-F,
50-CAACTAGGAAACCCCAGGCG - 30; CpG3-R, 50-ACAG
GGAGG AGGCAGAGGAG- 30. To evaluate the level of
histone acetylation following 5-aza-dC or TSA treatment, the
ratio was determined by quantifying the intensities of the PCR
product in immunoprecipitated DNA vs 1:25 diluted input
DNA (total chromatin) ampliﬁed by PCR in a linear range. To
evaluate the level of histone acetylation over methylation, the
ratio was determined by quantifying the intensities of the PCR
products from ChIP with acetylation- or methylation-speciﬁc
histone H3 (monomethyl K9) antibodies (Upstate, Chicago,
IL, USA). Each ChIP assay also included RNA polymerase II
(Pol II) and control immunoglobulin (Ig)G. Negative control
primers ﬂanking a region of genomic DNA between the
GAPDH gene and CNAP1 gene (For: 50-ATGGTTGC
CACTGGGGATCT-30 and Rev: 50-TGCCAA AGCCTA
GGGGAAGA-30) were also included as a control for each
ChIP analysis. PCR conditions for all primers are the same
as indicated above. ChIP analysis was repeated three times.
To determine the acetylation status of chromatin following
5-aza-dC or TSA treatment, OV207 cells were treated with
2.5mM 5-aza-dC and/or 1mg/ml TSA for 48–72 h.
Attenuation of cisplatin-induced cytotoxicity following siRNA-
mediated downregulation of HSulf-1 in ovarian cancer cell lines
OV167 and OV202 cells with endogenous expression of HSulf-
1 transfected with siRNAs for 2 days were treated with
increasing concentrations of cisplatin ranging from 2.5 to
30mM for 24 h in a 96-well plate. Cells were then incubated
in fresh medium for additional 3–4 days. To quantify viable
cells, cells were incubated for 2 h with MTT by adding 20 ml of
5mg/ml MTT into each well. Cells were then washed with
phosphate-buffered saline and solubilized with 100 ml dimethyl
sulfoxide. Absorbance was read at l¼ 570 nm and survival was
calculated as a percentage of vehicle-treated controls.
Rescue of RNA interference (RNAi)
For rescue of RNAi, OV167 cells were initially transfected
with HSulf-1siRNA targeted to the 30-UTR (GCUACCCU
GGGUACCUUUG ). Scr siRNA (CCUAGGUGCAUCCC
GUUUG) served as controls. Twenty-four hours later, cells
were transfected with plasmid carrying HSulf-1ORF and
empty vector constructs using Lipofectamine Plus (Invitrogen,
Carlsbad, CA, USA). As RNAi is targeted toward the 30 UTR
of HSulf-1 mRNA, the mRNA encoded from the plasmid
containing HSulf-1 ORF does not contain the 30UTR and
therefore is resistant to RNAi.
In situ hybridization
Speciﬁc human HSulf-1 riboprobes were generated by RT–PCR
using the following primer pairs: HSulf-1: sense, 50-ACTGTA
CCAATCGGCCAGAG-30; antisense, 50-CCTCCTTGAATG
GGTGAAGA-30. RNA in situ hybridization was as described
previously (Qian et al., 2004).
Analysis of chemoresponse in ovarian cancer
Contingency tables containing levels of HSulf-1 staining and
tumor responses to chemotherapy were generated and two-
sided w2 analysis was performed using the Prism statistical
software (GraphPad Software Inc., San Diego, CA, USA).
Criteria for patient selection and response evaluation were as
described previously (Chien et al., 2006)
TMA Construction and Digital imaging system were as
previously described (Chien et al., 2006).
Statistical analysis
Contingency tables containing levels of HSulf-1 staining and
tumor responses to chemotherapy were generated, and two-
sided w2 analysis was performed using the Prism statistical
software (GraphPad Software Inc.). Po 0.05 (a¼ 0.05) is
considered statistically signiﬁcant.
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